Cassava Sciences Inc vs Pinterest Inc — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while Pinterest Inc trades at $22.9 (market cap $13.45B). The key difference: Pinterest Inc is far larger — about 281.7× Cassava Sciences Inc's market cap, and Pinterest Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | PINS | |
|---|---|---|
Market Cap | $47.75M | $13.45B |
Sector | Health | Media |
52-Week High | $4.64 | $37.95 |
52-Week Low | $0.87 | $15.42 |
Enterprise Value | -$34.93M | $13.37B |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
Pinterest (PINS) trades at $24.37, up 2.91% with strong technical momentum as moving averages signal bullish sentiment. The company demonstrates solid fundamental performance with Q2 2026 EPS beating estimates at $0.43 versus $0.36 expected, marking the third consecutive quarterly beat. Revenue growth remains robust at 18% year-over-year, reaching $1.18 billion in Q2 2026, while maintaining a healthy gross profit margin of 79.47%.
The investment outlook appears favorable with 54% analyst buy ratings and a $28.69 consensus price target representing 18% upside potential. However, risks include intense advertising competition from Meta and slowing revenue guidance for Q3 2026. The stock offers value at current levels given strong AI-driven ad growth and record user metrics, though investors should monitor competitive pressures and execution on international expansion.
Trailing returns across standard periods
Latest headlines on both assets
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →